SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMC NEWS

TMCNET eNEWSLETTER SIGNUP

Alder BioPharmaceuticals® to Present at Two Upcoming November Investor Conferences
[November 08, 2018]

Alder BioPharmaceuticals® to Present at Two Upcoming November Investor Conferences


BOTHELL, Wash., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it will webcast a business overview and update by Bob Azelby, Alder’s president and chief executive officer, at each of the following upcoming healthcare conferences:

  • Credit Suisse 27th Annual Healthcare Conference at 4:00 p.m. MT on Wednesday, November 14, 2018 in Scottsdale, AZ.
  • Piper Jaffray 30th Annual Healthcare Conference at 12:00 p.m. ET on Wednesday, November 28, 2018 in New York, NY.

A live audio webcast of each event can be accessed on the Events & Presentations page of the Investors section of Alder's website at http://www.alderbio.com, or by following the link belowin your web browser. An archived replay of the webcast will be available on Alder's website for at least 30 days after each live event concludes.



About Alder BioPharmaceuticals, Inc.
Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Alder’s lead product candidate, eptinezumab, is a monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. Unlike other CGRP inhibitors, eptinezumab was specifically designed as an infusion therapy to address significant patient need. Alder is also developing ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) for migraine prevention. For more information, please visit www.alderbio.com.

Investor Relations Contact:                                        
Michael Schaffzin
Stern Investor Relations, Inc.
212.362.1200
michael@sternir.com


Media Contact: 
Ashley Cadle
TogoRun
a.cadle@togorun.com
310.463.0143

Alder 1C Logo with R (002) (1).JPG


[ Back To TMCnet.com's Homepage ]







Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2018 Technology Marketing Corporation. All rights reserved | Privacy Policy